Overview: Routine Body Fluid Examination Panel
Introduction: The Routine Body Fluid Examination Panel is a diagnostic tool designed to analyze body fluid composition using sterile fluid samples. In India, body fluid analysis (pleural, peritoneal, synovial, pericardial) is essential for distinguishing exudative (infection, malignancy, TB) from transudative (heart failure, cirrhosis) effusions, with high yield in TB pleurisy (~30-40 percent of pleural effusions) and malignancy. High burden from underutilization in rural hospitals, limited clinical pathology labs, delayed appropriate management leading to untreated TB or missed malignancy. Per clinical pathology practices aligned with ICMR guidelines, the test employs microscopy for cell count, protein, glucose, and differential counts over 1-2 days with high accuracy, valuable for effusion workup in resource-limited settings. This diagnostic falls under fluid analysis and targets patients with unexplained effusion/ascites, addressing accurate characterization to guide further tests (ADA, culture, cytology). With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise fluid evaluation and reducing complications. Its fluid-based approach ensures reliable cellular/biochemical analysis.
Other Names: Body Fluid Pnl.
FDA Status: FDA approved, CLIA certified for clinical pathology, compliant with 2025 standards.
Historical Milestone: Routine fluid analysis standard; in India, key in TB/oncology workup.
Purpose: The test assesses 19 parameters including cell count to guide body fluid evaluation, classify exudate/transudate, inform management.
Test Parameters: 1. Cell Count, 2. Protein, 3. Glucose, 4â€"19. Differential Counts & Markers.
Pretest Condition: No fasting required; patients should report effusion symptoms.
Specimen: 5 mL body fluid in 1 sterile container, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 24 hours with proper handling to preserve integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate processing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for analysis).
Medical History: Patients should provide details on effusion cause (TB, malignancy, heart failure), symptoms.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed fluid abnormalities including infection or malignancy, benefits of early detection, and minimal discomfort from fluid collection.
Procedural Considerations: The test involves sample processing using microscopy by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low cellularity can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal composition indicates etiology, necessitating specialist input. Normal may require follow-up.
Specialist Consultation: Pulmonologists or physicians should be consulted for management.
Additional Supporting Tests: Culture, ADA, cytology for confirmation.
Test Limitations: May miss low-cellularity malignancy; comprehensive approach required.
References: Indian Journal of Chest Diseases 2024, Fluid Analysis Studies India 2023.
